This review highlights the challenges and lack of specific evidence for prescribing new oral anticoagulants in frail older patients, emphasizing the need for careful extrapolation of trial data.
No takes yet. Share an insight, caveat, or question.
NOAC safety concerns in frail elderly persist without specific antidotes or monitoring; leaves open need for targeted trials before broader adoption.
Brooy et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: